4-(2-phenylsulfanyl-phenyl)-piperidine derivatives as serotonin reuptake inhibitors

Details for Australian Patent Application No. 2004226838 (hide)

Owner H. Lundbeck A/S

Inventors Puschl, Ask; Bryan, Stensbol Tine; Jorgensen, Morten; Bang-Andersen, Benny; Ruhland, Thomas

Agent Watermark

Pub. Number AU-B-2004226838

PCT Pub. Number WO2004/087156

Priority PA200300520 04.04.03 DK

Filing date 2 April 2004

Wipo publication date 14 October 2004

Acceptance publication date 12 February 2009

International Classifications

A61P 25/00 (2006.01) Drugs for disorders of the nervous system

C07D 211/24 (2006.01) Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings

C07D 405/12 (2006.01) Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom

Event Publications

27 October 2005 PCT application entered the National Phase

  PCT publication WO2004/087156 Priority application(s): WO2004/087156

1 December 2005 Amendment Made

  The nature of the amendment is: Delete priority details 60/460,528 4 Apr 2003 US

12 February 2009 Application Accepted

  Published as AU-B-2004226838

11 June 2009 Standard Patent Sealed

11 June 2009 Corrigenda

  Applications Accepted - Name Index Under the name H. Lundbeck A/S, Application No. 2004226838, under INID(72) correct the co-inventor name to read Bryan Stensbol, Tine

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004226849-Comminution device

2004226837-4-(2-phenyloxyphenyl)-piperidine or - 1,2,3,6-tetrahydropyridine derivatives as serotonin reuptake inhibitors